Pilot clinical trial was done using 30 children and 42 adult sickle-cell disorder patients for two years, showing that it reduced the incidence of crises profoundly in all the volunteers. Furthermore, hospital visitation and absenteeism from school and work were significantly reduced."
Research work on SOLAMIN confirms that SOLAMIN contains average or percentage sickling inhibition (prevention) of between 89.56 97.95% and 63.82 84.00% sickling reversal. SOLAMIN is also known to greatly enhance the physical development of Patients. (Research works by: Natural medicine and molecular Pharmaco-Biotechnology Laboratories, college of medicine, university of Lagos - Nigeria.)

.